<DOC>
	<DOCNO>NCT01783600</DOCNO>
	<brief_summary>The objective clinical evaluation evaluate immediate long-term ( 12 month ) outcome NanoCrossTM balloon catheter ( Covidien ) prospective , non-randomised , controlled investigation treatment patient critical limb ischemia ( Rutherford 4-5 ) due presence lesion minimally 10cm length level below-the-knee artery .</brief_summary>
	<brief_title>NanoCross BTK , Prospective , Non-randomized , Multicenter , Controlled Trial Evaluating Performance NanoCrossTM .014 Balloon Catheter Infrapopliteal Lesions</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Patient present rest pain minor tissue loss ( Rutherford class 4 5 ) Patient willing comply specify followup evaluation specify time Patient &gt; 18 year old Patient understand nature procedure provide write informed consent , prior enrolment study Patient project lifeexpectancy least 12 month Patient eligible treatment NanoCrossTM .014 balloon catheter ( Covidien ) Male , infertile female , female child bear potential practicing acceptable method birth control negative pregnancy test within 7 day prior study procedure De novo lesion restenotic lesion PTA infrapopliteal artery , suitable endovascular therapy Total target lesion length minimally 100mm Target vessel diameter visually estimate &gt; 1.5mm &lt; 4.0mm Guidewire delivery system successfully traverse lesion At least one nonoccluded crural artery angiographically document run foot . Patient refuse treatment The reference segment diameter suitable available balloon design Untreated flowlimiting inflow lesion Perioperative unsuccessful ipsilateral percutaneous vascular procedure treat inflow disease prior enrollment Any previous surgery target vessel ( include prior ipsilateral crural bypass ) Aneurysm target vessel Target lesion severe calcification determine physician 's discretion Nonatherosclerotic disease result occlusion ( e.g . embolism , Buerger 's disease , vasculitis ) Severe medical comorbidities ( untreated CAD/CHF , severe COPD , metastatic malignancy , dementia , etc ) medical condition would preclude compliance study protocol 1year life expectancy Major distal amputation ( transmetatarsal ) study limb non study limb Septicemia bacteremia Any previously know coagulation disorder , include hypercoagulability Contraindication anticoagulation antiplatelet therapy Known allergy contrast medium adequately premedicated prior study procedure Patient know hypersensitivity heparin , include patient previous incidence heparininduced thrombocytopenia ( HIT ) type II Currently participate another clinical research trial Angiographic evidence intraarterial thrombus atheroembolism inflow treatment Target lesion access perform transfemoral approach .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Infrapopliteal lesion</keyword>
	<keyword>balloon catheter</keyword>
</DOC>